Article info
PDFOriginal research
Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study
- Correspondence to Dr Mitchell Kamrava, Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California, USA; mitchell.kamrava{at}cshs.org
Citation
Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study
Publication history
- Received August 24, 2021
- Accepted November 22, 2021
- First published December 15, 2021.
Online issue publication
February 07, 2022
Article Versions
- Previous version (7 February 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.